Emerging guidelines for use of NSAID therapy to optimize cataract surgery patient care.
This analysis provides guidelines for the proper use of topical ophthalmic nonsteroidal anti-inflammatory drugs (NSAIDs), discusses their effect on inflammation, and their role in the prevention of cystoid macular edema (CME). A novel treatment strategy is presented for recommended topical ophthalmic NSAID dosing in patient populations based on risk factors for CME. The article reviews current topical ophthalmic NSAIDs, as well as a newest generation of pro-drug NSAIDs. In addition, combination therapy of NSAIDs and corticosteroids are discussed, along with a general review of therapeutic guidelines for dosing regimens, and benefits and risks of therapy. The goal of this analysis is to provide a suggested therapeutic regimen with topical NSAIDs to assist in achieving optimal clinical and functional outcomes.
O'Brien
T P
TP
The Wilmer Ophthalmology Institute, The Johns Hopkins Hospital, Baltimore, MD 21287-0682, USA. tobrien@jhmi.edu
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use*; D002387:Cataract Extraction; D004359:Drug Therapy, Combination; D006801:Humans; D008269:Macular Edema / Q000188:drug therapy* / Q000517:prevention & control; D011182:Postoperative Care; D011183:Postoperative Complications / Q000188:drug therapy* / Q000517:prevention & control
D000305:Adrenal Cortex Hormones; D000894:Anti-Inflammatory Agents, Non-Steroidal